Mutant enzyme ‘helps prostate cancer to spread and become more aggressive’
Researchers hope the findings might offer new treatment options for aggressive prostate cancer.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Scientists have identified how a specific substance plays a key role in helping prostate cancer to spread and become harder to treat.
They hope the findings might offer new treatment options for aggressive prostate cancer.
A team at Nottingham Trent University found that “transglutaminase 2” (TG2), which is abundant in many of the body’s cells, is responsible for driving a process which leads to the progression and spreading of the disease.
In the UK, prostate cancer is the most common cancer in men – with more than 52,000 diagnosed every year.
This finding has opened a significant pathway for understanding other key mechanisms prostate cancer cells utilise to evade key regulatory pathways
Early prostate cancer cells require the male hormone androgen to grow.
However they can become androgen-independent and therefore harder to treat with current therapies, as they advance.
Researchers suggest that until now it has not been clear how that process occurs.
Dr Adeola Atobatele, a scientist on the study, said: “This finding has opened a significant pathway for understanding other key mechanisms prostate cancer cells utilise to evade key regulatory pathways.”
The new study found that a mutant form of TG2 is overproduced in prostate cancer and remains trapped inside the nucleus of cells.
There it restricts the levels of androgen response – making cancer cells the more aggressive androgen-independent.
It also increases expression of the protein mucin-1, which is known to be responsible for the growth and spreading of cancer.
Mucin-1 forms a mucous barrier on cell surfaces which protects cancer cells, researchers found.
When researchers analysed biopsies of prostate cancer, they identified increased levels of TG2.
Based on the findings, the team proposes that controlling the activity of TG2 and mucin-1 may offer a new therapeutic option for aggressive prostate cancer.
Lead scientist Dr Elisabetta Verderio Edwards, from Nottingham Trent University’s School of Science and Technology, said: “We wanted to explore why some cancer cells become androgen-independent and as a result more aggressive and harder to treat.
“Transglutaminase is a multifunctional protein in all tissues and is involved in multiple processes.
“We have now deepened our understanding of its key role in aggressive disease in prostate cancer patients.
“Understanding this pathway is incredibly important.
“This process plays a key role in cancer’s ability to evade treatment and so warrants further investigation in terms of potential future treatment and therapy.”
The latest study, which also involved the Polyclinic Hospital University (University of Messina) in Italy, is published in the journal Cell Death and Disease.